Valuation: PharmaEngine, Inc.

Market Cap 9.12B 282M 247M 231M 212M 397M 26.97B 407M 2.74B 1.07B 13.35B 1.06B 1.03B 46.13B P/E 2024
7.42x
P/E 2025 26.2x
Enterprise Value 4.45B 137M 121M 113M 103M 193M 13.15B 198M 1.34B 522M 6.51B 515M 504M 22.5B EV / Sales 2024
3.61x
EV / Sales 2025 5.97x
Free-Float
61.82%
Yield 2024
6.64%
Yield 2025 2.84%
1 day-1.24%
1 week-7.16%
Current month+4.10%
1 month+6.72%
3 months+16.09%
6 months-6.75%
Current year-9.80%
1 week 62.1
Extreme 62.1
67.8
1 month 60.6
Extreme 60.6
70.5
Current year 53
Extreme 53
74
1 year 53
Extreme 53
81.5
3 years 53
Extreme 53
123
5 years 53
Extreme 53
150.5
10 years 33.1
Extreme 33.1
212.51
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2021-05-16
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 2018-01-18
Director/Board Member - 2018-05-14
Director/Board Member - 2019-06-12
Change 5-day change 1-year change 3-year change Capi.($)
-1.24%-7.16%-16.56%-25.64% 285M
+2.61%+7.16%-0.93%+13.91% 47.88B
+1.90%+24.70%+27.25%+9.47% 40.55B
-1.60%-1.15%+388.84%+603.70% 39.09B
-0.98%+2.28%+7.02%+45.34% 36.75B
+1.47%+5.82%+5.76%+43.52% 27.96B
-0.94%+0.05% - - 16.77B
+2.44%+10.76%+30.59%+129.56% 15.94B
-1.14%+6.52%-3.80%-29.33% 13.81B
+0.18%-2.75%+3.22%+10.14% 13.55B
Average +0.27%+3.65%+49.04%+88.96% 25.26B
Weighted average by Cap. +0.61%+4.91%+72.74%+124.34%

Financials

2024 2025
Net sales 2.52B 77.87M 68.42M 63.87M 58.62M 110M 7.46B 112M 757M 296M 3.69B 292M 286M 12.76B 911M 28.13M 24.71M 23.07M 21.17M 39.63M 2.69B 40.61M 274M 107M 1.33B 106M 103M 4.61B
Net income 1.75B 54.04M 47.48M 44.32M 40.68M 76.14M 5.18B 78.02M 526M 206M 2.56B 203M 198M 8.85B 388M 11.96M 10.51M 9.81M 9M 16.86M 1.15B 17.27M 116M 45.5M 567M 44.91M 43.94M 1.96B
Net Debt -3.85B -119M -105M -97.54M -89.52M -168M -11.39B -172M -1.16B -452M -5.64B -447M -437M -19.49B -4.67B -144M -127M -118M -109M -203M -13.82B -208M -1.4B -549M -6.84B -542M -530M -23.64B
Logo PharmaEngine, Inc.
PharmaEngine Inc is a Taiwan-based company primarily engaged in new drug development. The main business is the research and development of various cancer drugs. ONIVYDE is a novel and stable encapsulated form of the marketed chemotherapy drug irinotecan in a long-circulating nanoliposome for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. It has received marketing approvals in Taiwan, the United States, the European Union, Singapore, South Korea, Japan, China and other regions. PEP07, a checkpoint kinase 1 (CHK1) inhibitor, which targets the deoxyribonucleic acid damage response (DDR) network, is in Phase 1 clinical trial stage and its target is to treat hematologic cancers such as acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), and solid tumors.
Employees
45
Date Price Change Volume
26-07-29 NT$63.50 -1.24% 704,069
26-07-28 NT$64.30 -2.28% 593,776
26-07-27 NT$65.80 -0.15% 372,024
26-07-24 NT$65.90 -1.35% 538,914
26-07-23 NT$66.80 -2.34% 795,983
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4162 Stock